DISCONTINUATION OF BTK INHIBITOR MONOTHERAPY IN CLL PATIENTS WITHOUT DISEASE PROGRESSION: A REAL‐WORLD STUDY FROM THE SPANISH CLL GROUP (GELLC) | Publicación